Urinary Marker Panels for Aggressive Prostate Cancer Detection

Overview

Journal Sci Rep

Specialty Science

Date 2022 Sep 1

PMID 36050450

Authors

Tung-Shing Mamie Lih

Mingming Dong

Leslie Mangold

Alan Partin

Hui Zhang

Affiliations

Soon will be listed here.

Abstract

Majority of patients with indolent prostate cancer (PCa) can be managed with active surveillance. Therefore, finding biomarkers for classifying patients between indolent and aggressive PCa is essential. In this study, we investigated urinary marker panels composed of urinary glycopeptides and/or urinary prostate-specific antigen (PSA) for their clinical utility in distinguishing non-aggressive (Grade Group 1) from aggressive (Grade Group ≥ 2) PCa. Urinary glycopeptides acquired via data-independent acquisition mass spectrometry (DIA-MS) were quantitatively analyzed, where prostatic acid phosphatase (ACPP), clusterin (CLU), alpha-1-acid glycoprotein 1 (ORM1), and CD antigen 97 (CD97) were selected to be evaluated in various combinations with and without urinary PSA. Targeted parallel reaction monitoring (PRM) assays of the glycopeptides from urinary ACPP and CLU were investigated along with urinary PSA for the ability of aggressive PCa detection. The multi-urinary marker panels, combined via logistic regression, were statistically evaluated using bootstrap resampling and validated by an independent cohort. Majority of the multi-urinary marker panels (e.g., a panel consisted of ACPP, CLU, and Urinary PSA) achieved area under the curve (AUC) ranged from 0.70 to 0.85. Thus, multi-marker panels investigated in this study showed clinically meaningful results on aggressive PCa detection to separate Grade Group 1 from Grade Group 2 and above warranting further evaluation in clinical setting in future.

Citing Articles

GP-Marker facilitates the analysis of intact glycopeptide quantitative data at different levels.

Liu Q, Zhu H, Fang Z, Dong M, Qin H, Ye M Anal Bioanal Chem. 2024; 417(5):989-999.

PMID: 39207492 DOI: 10.1007/s00216-024-05499-z.

Urine biomarkers can predict prostate cancer and PI-RADS score prior to biopsy.

Pavlovic B, Brautigam K, Dartiguenave F, Martel P, Rakauskas A, Cesson V Sci Rep. 2024; 14(1):18148.

PMID: 39103428 PMC: 11300834. DOI: 10.1038/s41598-024-68026-1.

Symptomatic Benign Prostatic Hyperplasia with Suppressed Epigenetic Regulator HOXB13 Shows a Lower Incidence of Prostate Cancer Development.

Barashi N, Li T, Angappulige D, Zhang B, OGorman H, Nottingham C Cancers (Basel). 2024; 16(1).

PMID: 38201640 PMC: 10778073. DOI: 10.3390/cancers16010213.

Reliability of Systematic and Targeted Biopsies versus Prostatectomy.

Guan T, Sidana A, Rao M Bioengineering (Basel). 2023; 10(12).

PMID: 38135986 PMC: 10740569. DOI: 10.3390/bioengineering10121395.

Development of a predictive model to distinguish prostate cancer from benign prostatic hyperplasia by integrating serum glycoproteomics and clinical variables.

Gabriele C, Aracri F, Prestagiacomo L, Rota M, Alba S, Tradigo G Clin Proteomics. 2023; 20(1):52.

PMID: 37990292 PMC: 10662699. DOI: 10.1186/s12014-023-09439-4.

References

Kinsella N, Stattin P, Cahill D, Brown C, Bill-Axelson A, Bratt O . Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review. Eur Urol. 2018; 74(3):261-280. PMC: 6198662. DOI: 10.1016/j.eururo.2018.02.026. View

Berman D, Epstein J . When is prostate cancer really cancer?. Urol Clin North Am. 2014; 41(2):339-46. DOI: 10.1016/j.ucl.2014.01.006. View

Rodriguez M, Bajo-Santos C, Hessvik N, Lorenz S, Fromm B, Berge V . Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes. Mol Cancer. 2017; 16(1):156. PMC: 5629793. DOI: 10.1186/s12943-017-0726-4. View

Hendriks R, van Oort I, Schalken J . Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions. Prostate Cancer Prostatic Dis. 2016; 20(1):12-19. DOI: 10.1038/pcan.2016.59. View

Choo R, Klotz L, Danjoux C, Morton G, Deboer G, Szumacher E . Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol. 2002; 167(4):1664-9. View

Liu Y, Chen J, Sethi A, Li Q, Chen L, Collins B . Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-acylethanolamine acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness. Mol Cell Proteomics. 2014; 13(7):1753-68. PMC: 4083113. DOI: 10.1074/mcp.M114.038273. View

Donovan M, Noerholm M, Bentink S, Belzer S, Skog J, ONeill V . A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result. Prostate Cancer Prostatic Dis. 2015; 18(4):370-5. DOI: 10.1038/pcan.2015.40. View

Li Q, Lih T, Wang Y, Hu Y, Hoti N, Chan D . Improving the detection of aggressive prostate cancer using immunohistochemical staining of protein marker panels. Am J Cancer Res. 2022; 12(3):1323-1336. PMC: 8984898. View

Sanda M, Cadeddu J, Kirkby E, Chen R, Crispino T, Fontanarosa J . Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options. J Urol. 2017; 199(3):683-690. DOI: 10.1016/j.juro.2017.11.095. View

10.

Zhao F, Olkhov-Mitsel E, Kamdar S, Jeyapala R, Garcia J, Hurst R . A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer. Clin Epigenetics. 2018; 10(1):147. PMC: 6260648. DOI: 10.1186/s13148-018-0575-z. View

11.

Ilic D, Djulbegovic M, Jung J, Hwang E, Zhou Q, Cleves A . Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018; 362:k3519. PMC: 6283370. DOI: 10.1136/bmj.k3519. View

12.

OReilly E, Tuzova A, Walsh A, Russell N, OBrien O, Kelly S . epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer. JCO Precis Oncol. 2019; 2019. PMC: 6383793. DOI: 10.1200/PO.18.00134. View

13.

Whitworth H, Bhadel S, Ivey M, Conaway M, Spencer A, Hernan R . Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen. PLoS One. 2012; 7(6):e38950. PMC: 3384611. DOI: 10.1371/journal.pone.0038950. View

14.

Dong M, Lih T, Chen S, Cho K, Eguez R, Hoti N . Urinary glycoproteins associated with aggressive prostate cancer. Theranostics. 2020; 10(26):11892-11907. PMC: 7667684. DOI: 10.7150/thno.47066. View

15.

Leyten G, Hessels D, Jannink S, Smit F, de Jong H, Cornel E . Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2012; 65(3):534-42. DOI: 10.1016/j.eururo.2012.11.014. View

16.

Chen R, Rumble R, Loblaw D, Finelli A, Ehdaie B, Cooperberg M . Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2016; 34(18):2182-90. DOI: 10.1200/JCO.2015.65.7759. View

17.

Ergun A, Lawrence C, Kohanski M, Brennan T, Collins J . A network biology approach to prostate cancer. Mol Syst Biol. 2007; 3:82. PMC: 1828752. DOI: 10.1038/msb4100125. View

18.

Chen S, Dong M, Yang G, Zhou Y, Clark D, Lih T . Glycans, Glycosite, and Intact Glycopeptide Analysis of N-Linked Glycoproteins Using Liquid Handling Systems. Anal Chem. 2019; 92(2):1680-1686. PMC: 7331092. DOI: 10.1021/acs.analchem.9b03761. View

19.

Rittenhouse H, Blase A, Shamel B, Schalken J, Groskopf J . The long and winding road to FDA approval of a novel prostate cancer test: our story. Clin Chem. 2012; 59(1):32-4. DOI: 10.1373/clinchem.2012.198739. View

20.

Klotz L . Contemporary approach to active surveillance for favorable risk prostate cancer. Asian J Urol. 2019; 6(2):146-152. PMC: 6488691. DOI: 10.1016/j.ajur.2018.12.003. View